Inventiva Announces the Initiation of Its Pivotal Phase III Clinical Trial Evaluating Lanifibranor in NASH

Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses and other diseases, announced the initiation of its NATiV3 Phase III clinical trial evaluating lanifibranor for the treatment of NASH.